PH-ILD Market Set to Grow Substantially Through 2034, DelveInsight Projects

DelveInsight's "Pulmonary Hypertension Associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pulmonary Hypertension Associated with Interstitial Lung Disease, historical and forecasted epidemiology as well as the Pulmonary Hypertension Associated with Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the PH-ILD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; PH-ILD Market Forecast
https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report:
• The PH-ILD market size was valued approximately USD 1,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In September 2025, Pulmovant, a clinical-stage biotech focused on pulmonary disease therapies and a Roivant (Nasdaq: ROIV) company, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to mosliciguat. This novel, once-daily inhaled soluble guanylate cyclase (sGC) activator is under investigation for treating Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), a progressive, life-threatening condition with a high unmet medical need.
• In June 2025, Halo Biosciences, the developer of HB-1614, reported that a Phase 2a study of the oral therapy candidate indicated the drug is safe and may enhance exercise capacity and quality of life in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings were published following the SATURN clinical trial (NCT05128929).
• The US PH-ILD market was valued at around USD 2 billion in 2024 and is expected to grow with the introduction of new therapies.
• The EU4 and UK PH-ILD market was estimated at around USD 480 million in 2024, representing roughly 23% of the total 7MM market, and is projected to grow by 2034.
• In 2024, the UK led the European PH-ILD market with roughly USD 120 million, followed by Germany at about USD 100 million, and Spain at approximately USD 70 million.
• In 2024, the diagnosed prevalence of PH-ILD in the US indicated a slightly higher burden among males, with around 42,000 cases versus 39,000 in females. This gender disparity is projected to increase by 2034, suggesting possible differences in disease susceptibility or progression.
• In 2024, approximately 69,000 individuals in the EU4 and the UK were diagnosed with PH-ILD, highlighting a significant and increasing regional disease burden.
• In France, CTD-associated PH-ILD showed the highest diagnosed prevalence at nearly 4,000 cases in 2024, whereas hypersensitivity pneumonitis had the lowest, with just over 500 cases.
• In Japan, more than 28,000 diagnosed cases of PH-ILD were reported in 2024, with projections showing an increase by 2034, reflecting a growing disease burden.
• Key PH-ILD Companies: United Therapeutics Corp., Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others
• Key PH-ILD Therapies: TYVASO/TYVASO DPI (treprostinil), TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
• The PH-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline products will significantly revolutionize the Pulmonary Hypertension Associated with Interstitial Lung Disease market dynamics.

PH-ILD Overview
An elevated pulmonary arterial pressure (PAP) of many etiologies that can cause significant morbidity is known as pulmonary hypertension (PH), a significant consequence of interstitial lung disease (ILD). The World Symposium on PH defined five clinical groups for PH based on differences in pathological findings among the groups, such as the underlying cause of the disease, clinical presentation, and hemodynamic features.

Get a Free sample for the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology
The Pulmonary Hypertension Associated with Interstitial Lung Disease epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Segmentation:
The Pulmonary Hypertension Associated with Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of PH-ILD
• Prevalent Cases of PH-ILD by severity
• Gender-specific Prevalence of PH-ILD
• Diagnosed Cases of Episodic and Chronic PH-ILD
Download the report to understand which factors are driving PH-ILD epidemiology trends @ Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pulmonary Hypertension Associated with Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Hypertension Associated with Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Pulmonary Hypertension Associated with Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies and Key Companies
• TYVASO/TYVASO DPI (treprostinil): United Therapeutics Corp.
• Treprostinil Palmitil: Insmed Incorporated
• TPIP: Insmed Incorporated
• INOpulse: Bellerophon Therapeutics
• Inhaled Treprostinil: United Therapeutics
• Riociguat (Adempas, BAY63-2521): Bayer
• Bardoxolone methyl: Biogen

Discover more about therapies set to grab major Pulmonary Hypertension Associated with Interstitial Lung Disease market share @ Pulmonary Hypertension Associated with Interstitial Lung Disease Treatment Landscape
https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

PH-ILD Market Drivers
• The worldwide population and improvement in diagnosis are resulting in a rise in PH prevalence associated with several types of ILDs. This rise in cases is supposed to strengthen the market in the future.
• Treatment demand for PH-ILD is increasing, with a lack of therapies to manage the disease burden. Hence, the market is vast and up for any key player developing a novel therapy.

PH-ILD Market Barriers
• Expected approval of potential therapies can increase market size.
• Lucrative opportunities for market growth in the studied countries, owing to the presence of a large pool of patients suffering from PH-ILD

Scope of the PH-ILD Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pulmonary Hypertension Associated with Interstitial Lung Disease Companies: United Therapeutics Corp., Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others
• Key Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies: TYVASO/TYVASO DPI (treprostinil), TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
• Pulmonary Hypertension Associated with Interstitial Lung Disease Therapeutic Assessment: Pulmonary Hypertension Associated with Interstitial Lung Disease current marketed and Pulmonary Hypertension Associated with Interstitial Lung Disease emerging therapies
• Pulmonary Hypertension Associated with Interstitial Lung Disease Market Dynamics: Pulmonary Hypertension Associated with Interstitial Lung Disease market drivers and Pulmonary Hypertension Associated with Interstitial Lung Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pulmonary Hypertension Associated with Interstitial Lung Disease Unmet Needs, KOL's views, Analyst's views, Pulmonary Hypertension Associated with Interstitial Lung Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432,
State: Las Vegas NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.